Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glucagon like peptide 1 agonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Glucagon like peptide 1 agonist. Displaying page 1 of 1.
    EudraCT Number: 2022-003853-70 Sponsor Protocol Number: PNRR-MR1-2022-12375914 Start Date*: 2023-05-02
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose­ dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi...
    Medical condition: Wolfram syndrome type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10078338 Wolfram syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003343-11 Sponsor Protocol Number: GLP1ALCOHOL Start Date*: 2017-04-12
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence?
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10001125 Addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001221-14 Sponsor Protocol Number: E.G.R.A.B.I.N.S1 Start Date*: 2016-06-17
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in persons without cerebrovascular disease.
    Medical condition: This is a healthy control group which is to be compared with patients with stroke.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001219-18 Sponsor Protocol Number: E.G.R.A.B.I.S1 Start Date*: 2016-06-17
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in ischemic stroke patients
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002259-14 Sponsor Protocol Number: TRG12-05 Start Date*: 2013-11-27
    Sponsor Name:University of Oxford
    Full Title: The effect of lixisenatide in type 1 diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000102-28 Sponsor Protocol Number: AFJ2020-1 Start Date*: 2020-08-19
    Sponsor Name:Mental Healt Center Copenhagen
    Full Title: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the an...
    Medical condition: Schizophrenia spectrum disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10052792 Schizophrenia, undifferentiated type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005174-11 Sponsor Protocol Number: U1111-1166-6923 Start Date*: 2015-10-01
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positiv...
    Medical condition: Beta-cell function in C-peptide positive type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001371-37 Sponsor Protocol Number: GDM-TREAT Start Date*: 2012-07-10
    Sponsor Name:Dr. med. Tina Vilsbøll
    Full Title: The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus
    Medical condition: Gestational diabetes mellitus Non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10018210 Gestational diabetes mellitus LLT
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004850-32 Sponsor Protocol Number: EFC13794 Start Date*: 2016-06-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabe...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002155-25 Sponsor Protocol Number: TAK-448-2001 Start Date*: 2014-11-17
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism
    Medical condition: Hypogonadotropic Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004452-42 Sponsor Protocol Number: STABIL-NOR Start Date*: 2022-12-14
    Sponsor Name:Helse Bergen HF
    Full Title: An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients (STABIL-NOR –...
    Medical condition: Drug induced weight gain from anti-psychotic drug treatment in patients with schizophrenia. Treatment with semaglutide, a glucagon-like peptide receptor agonist used to treat diabetes and approv...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001485-35 Sponsor Protocol Number: LPS17007 Start Date*: 2022-10-03
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naï...
    Medical condition: Type 2 Diabetes Mellitus and Renal Impairment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002977-69 Sponsor Protocol Number: BEYOND Start Date*: 2019-11-14
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: Durability of combination of insulin and GLP-1 receptor agonist or SGLT-2 inhibitors versus basal bolus insulin regimen in type 2 diabetes: a randomized controlled trial
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000065-16 Sponsor Protocol Number: DS102A-07-CV1 Start Date*: 2020-08-11
    Sponsor Name:Afimmune Ltd.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab...
    Medical condition: Hypertriglyceridemia and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 09:12:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA